These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 10990198

  • 1. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C, Dalton JT, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, Schuetz EG.
    Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
    [Abstract] [Full Text] [Related]

  • 2. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y.
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
    Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H.
    Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
    Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P.
    Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
    [Abstract] [Full Text] [Related]

  • 10. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
    Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
    [Abstract] [Full Text] [Related]

  • 11. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
    Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K.
    Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
    [Abstract] [Full Text] [Related]

  • 12. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
    Patel J, Buddha B, Dey S, Pal D, Mitra AK.
    Am J Ther; 2004 Mar; 11(4):262-77. PubMed ID: 15266218
    [Abstract] [Full Text] [Related]

  • 13. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4.
    Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y.
    J Pharmacol Exp Ther; 2000 Apr; 293(1):230-6. PubMed ID: 10734174
    [Abstract] [Full Text] [Related]

  • 14. Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.
    Takenaka T, Kazuki K, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T, Abe S, Oshimura M, Kazuki Y.
    Drug Metab Pharmacokinet; 2017 Feb; 32(1):61-68. PubMed ID: 28139373
    [Abstract] [Full Text] [Related]

  • 15. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells.
    Bertilsson PM, Olsson P, Magnusson KE.
    J Pharm Sci; 2001 May; 90(5):638-46. PubMed ID: 11288108
    [Abstract] [Full Text] [Related]

  • 16. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
    Hayashi K, Sakaki T, Kominami S, Inouye K, Yabusaki Y.
    Arch Biochem Biophys; 2000 Sep 01; 381(1):164-70. PubMed ID: 11019832
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
    Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, Yokoi T.
    Drug Metab Dispos; 1999 Sep 01; 27(9):999-1004. PubMed ID: 10460798
    [Abstract] [Full Text] [Related]

  • 19. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
    Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, Löscher W.
    Br J Pharmacol; 2010 Jul 01; 160(6):1453-63. PubMed ID: 20590635
    [Abstract] [Full Text] [Related]

  • 20. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
    Becquemont L, Glaeser H, Drescher S, Hitzl M, Simon N, Murdter TE, Heinkele G, Hofmann U, Schaefer C, Burk O, Verstuyft C, Eichelbaum M, Fromm MF.
    Clin Pharmacol Ther; 2006 May 01; 79(5):449-60. PubMed ID: 16678547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.